Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
GPCR Analyst Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GPCR Stock 12 Month Forecast
Average Price Target
$69.20
▲(170.00% Upside)
| Highest Price Target$100.00 | Average Price Target$69.20 | Lowest Price Target$44.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$60
Buy
134.10%
Upside
Reiterated
09/23/25
LifeSci Capital
$75
Buy
192.63%
Upside
Reiterated
09/18/25
Promising Market Potential for Structure Therapeutics: Buy Rating Backed by Superior Trial Results and Market OpportunitiesIn addion to Lilly’s (NYSE: LLY) EASD presentaon on orfoglipron’s Phase 3 ATTAIN-1 data in obesity and concurrent publicaon in NEJM (note here), the company also released top-line results from ACHIEVE- 3, which was a Phase 3, open-label head-to-head trial comparing orforglipron to oral semaglude in type 2 diabecs (T2D) inadequately controlled on meormin (n=1,698). Consistent with prior observaons we flagged in our resumpon of coverage piece (link here, slide 21), which eluded to the parity or even superiority of orfoglipron vs other injectable increns in T2D, in ACHIEVE-3, orfoglipron significantly outperformed its approved oral pepde competor (Rybelsus [oral semaglude]) on lowering HbA1C and weight loss. Specifically, paents receiving 36mg orfoglipron experienced 2.2% reducons in HbA1C, versus a 1.4% reducon for 14mg oral semaglude (p<0.001).
Citizens JMP
$87
Buy
239.45%
Upside
Reiterated
09/17/25
Cantor Fitzgerald
$65
Buy
153.61%
Upside
Reiterated
09/17/25
J.P. Morgan
―
Buy
―
Reiterated
09/04/25
Citi
$60
Buy
134.10%
Upside
Reiterated
08/17/25
BMO Capital
$100
Buy
290.17%
Upside
Reiterated
08/11/25
Leerink Partners
$60→$44
Buy
71.67%
Upside
Reiterated
08/07/25
Stifel Nicolaus
$50
Buy
95.08%
Upside
Reiterated
08/07/25
Guggenheim
$92→$90
Buy
251.15%
Upside
Reiterated
08/06/25
William Blair
―
Buy
―
Reiterated
08/06/25
Clear Street
$61
Buy
138.00%
Upside
Initiated
07/30/25
Jefferies
$79
Buy
208.23%
Upside
Reiterated
06/05/25
Piper Sandler
$93
Buy
262.86%
Upside
Reiterated
06/03/25
Morgan Stanley
$118→$120
Buy
368.20%
Upside
Reiterated
05/12/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$60
Buy
134.10%
Upside
Reiterated
09/23/25
LifeSci Capital
$75
Buy
192.63%
Upside
Reiterated
09/18/25
Promising Market Potential for Structure Therapeutics: Buy Rating Backed by Superior Trial Results and Market OpportunitiesIn addion to Lilly’s (NYSE: LLY) EASD presentaon on orfoglipron’s Phase 3 ATTAIN-1 data in obesity and concurrent publicaon in NEJM (note here), the company also released top-line results from ACHIEVE- 3, which was a Phase 3, open-label head-to-head trial comparing orforglipron to oral semaglude in type 2 diabecs (T2D) inadequately controlled on meormin (n=1,698). Consistent with prior observaons we flagged in our resumpon of coverage piece (link here, slide 21), which eluded to the parity or even superiority of orfoglipron vs other injectable increns in T2D, in ACHIEVE-3, orfoglipron significantly outperformed its approved oral pepde competor (Rybelsus [oral semaglude]) on lowering HbA1C and weight loss. Specifically, paents receiving 36mg orfoglipron experienced 2.2% reducons in HbA1C, versus a 1.4% reducon for 14mg oral semaglude (p<0.001).
Citizens JMP
$87
Buy
239.45%
Upside
Reiterated
09/17/25
Cantor Fitzgerald
$65
Buy
153.61%
Upside
Reiterated
09/17/25
J.P. Morgan
―
Buy
―
Reiterated
09/04/25
Citi
$60
Buy
134.10%
Upside
Reiterated
08/17/25
BMO Capital
$100
Buy
290.17%
Upside
Reiterated
08/11/25
Leerink Partners
$60→$44
Buy
71.67%
Upside
Reiterated
08/07/25
Stifel Nicolaus
$50
Buy
95.08%
Upside
Reiterated
08/07/25
Guggenheim
$92→$90
Buy
251.15%
Upside
Reiterated
08/06/25
William Blair
―
Buy
―
Reiterated
08/06/25
Clear Street
$61
Buy
138.00%
Upside
Initiated
07/30/25
Jefferies
$79
Buy
208.23%
Upside
Reiterated
06/05/25
Piper Sandler
$93
Buy
262.86%
Upside
Reiterated
06/03/25
Morgan Stanley
$118→$120
Buy
368.20%
Upside
Reiterated
05/12/25
Best Analysts Covering Structure Therapeutics, Inc. Sponsored ADR
1 Month
xxx
Success Rate
11/17 ratings generated profit
Average Return
+8.72%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +8.72% per trade.
3 Months
xxx
Success Rate
9/17 ratings generated profit
Average Return
+10.70%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +10.70% per trade.
1 Year
Success Rate
7/17 ratings generated profit
Average Return
-0.78%
reiterated a buy rating 2 months ago
Copying David Risinger's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of -0.78% per trade.
2 Years
xxx
Success Rate
4/17 ratings generated profit
Average Return
-23.21%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 23.53% of your transactions generating a profit, with an average return of -23.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GPCR Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
13
16
14
13
15
Buy
2
1
1
1
2
Hold
0
0
0
0
0
Sell
2
2
0
0
0
Strong Sell
0
0
0
0
0
total
17
19
15
14
17
Each month's total comprises the sum of three months' worth of ratings.
GPCR Financial Forecast
GPCR Stock Forecast FAQ
What is GPCR’s average 12-month price target, according to analysts?
Based on analyst ratings, Structure Therapeutics, Inc. Sponsored ADR’s 12-month average price target is 69.20.
What is GPCR’s upside potential, based on the analysts’ average price target?
Structure Therapeutics, Inc. Sponsored ADR has 170.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GPCR a Buy, Sell or Hold?
Structure Therapeutics, Inc. Sponsored ADR has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is Structure Therapeutics, Inc. Sponsored ADR’s price target?
The average price target for Structure Therapeutics, Inc. Sponsored ADR is 69.20. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $44.00. The average price target represents 170.00% Increase from the current price of $25.63.
The highest analyst price target is $100.00 ,the lowest forecast is $44.00. The average price target represents 170.00% Increase from the current price of $25.63.
What do analysts say about Structure Therapeutics, Inc. Sponsored ADR?
Structure Therapeutics, Inc. Sponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of GPCR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.